Results with Lifescozul

Yamil Bravo - Thymus cancer- Resultados con LifEscozul™ Thymus cancer

Introduction to the case

In early 2017 Mr. Yamil started feeling unwell with cold symptoms, fever, bronchitis. Going to the doctor he was treated with antibiotics and kinesiology but had no effect. It was then decided to perform a scan where a thymus cancer was detected.

However, because it was in a very risky place and due to the proximity to blood vessels, it was determined by the doctors in his country to exclude the possibility of surgery.

When he was started on LifEscozul (the most effective formulation of the blue scorpion venom, escozul) Mr. Yamil's chances of survival and quality of life were extremely low.

Our Medical Group carefully analyzed Mr. Yamil's actual chances, and a dose with a high degree of concentration was decided. Weekly monitoring was also requested and we worked on progressive increases.

  • Clinical Data

    Yamil Bravo, Male, 53 years old at the beginning of treatment with LifEscozul.

  • Symptomatology

    He presented pain in ribs, neck and mild chest pain, as well as dysphonia.

  • Protocol Start

    July 2017.

  • Diagnostics

    Thymus carcinoma is a malignant tumor that has an unfavorable prognosis, it is classified into typical, atypical, small cell and large cell carcinomas, the latter category was proposed by Travis et al.

Background

In early 2017 Mr. Yamil started feeling unwell with cold symptoms, fever and bronchitis. Going to the doctor he was treated with antibiotics and kinesiology but had no effect.

It was then decided to perform a scan where a thymus cancer was detected.

However, because it was in a very risky place and due to the proximity to blood vessels, it was determined by the doctors in his country to exclude the possibility of surgery.

In June of the same year, in a subsequent examination, bone and lymph node metastases were detected. When he was started on LifEscozul (the most effective formulation of the blue scorpion venom, escozul) Mr. Yamil's chances of survival and quality of life were extremely low.

Our Medical Group carefully analyzed Mr. Yamil's actual chances, and a dose with a high degree of concentration was decided. Weekly monitoring was also requested and we worked on progressive increases.

Evolution with LifEscozul and actual results

Mr. Yamil's evolution was followed through his sister's reports. Communication has been fluid and direct with our Medical Team and has been fundamental in monitoring the results and making the necessary adjustments during the time of treatment.

In the first control CT scan in August 2017, one month into treatment with LifEscozul (the most effective formulation of the blue scorpion venom, escozul), an increase in the size of the mediastinal mass was observed with respect to the previous study, and in addition two secondary nodules were found in lungs.

When informed of this, our Medical Group decided to increase the dose because the aggressiveness of the cancer was even greater than initially thought.

We now proceed to increase the dose of LifEscozul (the most effective formulation of the blue scorpion venom, escozul).

Control #2 November 2017

The second control in November 2017, the studies indicate a decrease in the size of the supraclavicular adenopathies. Interestingly, Mr. Yamil's quality of life has started to recover gradually.

Despite such a good result, it was decided to increase the dose of LifEscozul (the most effective formulation of blue scorpion venom, escozul).

Control #3 January 2018

In December 2017 we proceeded to perform a chest CT scan, the result of which we received in January 2018. Among the most striking results, the decrease of the mediastinal mass stands out and the decrease of supraclavicular lymphadenopathies continues. Quality of life remains high, with appetite and zero pain.

Control # 7 June 2018, One year on LifEscozul treatment.

This is one of the most shocking results we have had, as the PET report sent in June 2018 describes that there are no hypermetabolic foci in the lower cervical region or mediastinum, which is indicative at that time that Mr. Yamil's cancer is not present.

It was decided, at that time, to discharge him by his oncologist in his country and he was instructed to follow up every 3 months for 5 years to be declared cancer free.

So far, July 2020, in all the studies performed, Mr. Yamil remains cancer free.

Resumen

When an aggressive cancer metastasizes, the chances of recovery are minimal. Coupled with the diminished quality of life, recovery becomes almost impossible.

The results have been beyond any possibility. The gradual evolution, from a decrease in metastases to the disappearance of the main tumor, is a truly spectacular result.

As of today, Mr. Yamil is free of the disease and is on his way to being declared cancer-free.

We could mention many heroes in this story, but we want to focus on the attitude of Mr. Yamil and his sister. In the communication with our doctors, and in the concern to keep us informed.

LifEscozul is a formulation currently in the process of being patented, and is the result of more than 17 years of continuous research.

We are the LifEscozul Group and results like Yamil's define us.

Next case

Raúl Manzano Murillo - Thyroid Cancer- Resultados con LifEscozul™

Raúl Manzano Murillo

Raul was detected with thyroid cancer in 2016 and underwent surgery in April 2016 for papillary thyroid carcinoma. At the end of 2017 he was detected new tumor nodules on both sides of his neck, with no possibility of operation due to fibrosis following surgery and iodotherapies received, he was offered no treatment option. View more